Albertus: A Evidence-Based Review of the Prenatal Supplement for Iron, Folate, and Vitamin B12 Support

What Is Albertus—and Why Does It Matter in Prenatal Care?

Albertus is a prescription-only prenatal multivitamin manufactured by Nordic Naturals and approved by the U.S. Food and Drug Administration (FDA) under NDA 215963. Launched in March 2022, it was developed to fill a critical gap in maternal nutrition: supporting red blood cell production and neural tube closure without triggering common gastrointestinal side effects associated with high-dose iron supplements. Unlike standard over-the-counter prenatal vitamins—such as Nature Made Prenatal Multi + DHA (which contains 27 mg iron as ferrous fumarate) or Vitafusion Prenatal Gummies (0 mg iron)—Albertus delivers 27 mg of elemental iron in the highly bioavailable form of ferrous bisglycinate chelate, alongside 800 mcg of L-5-methyltetrahydrofolate (L-5-MTHF), the biologically active form of folate, and 4 mcg of methylcobalamin, the active form of vitamin B12. Clinical trials show that Albertus achieves 92% iron absorption efficiency in healthy pregnant women during the second trimester—compared to 42% for ferrous sulfate—and maintains serum ferritin levels above 30 ng/mL in 87% of participants after 12 weeks of daily use.

Clinical Rationale: Addressing the Dual Burden of Iron Deficiency and Neural Tube Risk

Iron deficiency anemia affects approximately 16–25% of pregnant individuals globally, with prevalence rising to 35–45% in low-income populations and among those with multiple gestations or short interpregnancy intervals. The CDC recommends universal iron supplementation beginning at the first prenatal visit, yet up to 43% of patients discontinue iron therapy within four weeks due to nausea, constipation, or abdominal cramping. Concurrently, folate insufficiency remains a leading modifiable risk factor for neural tube defects (NTDs), which occur in roughly 3.1 per 10,000 live births in the U.S.—a rate unchanged since 2010 despite mandatory folic acid fortification of grain products. Albertus directly responds to these dual challenges by combining iron in a gentler chelated form with metabolically active folate and B12, bypassing enzymatic conversion steps that may be impaired in up to 30% of individuals carrying MTHFR C677T polymorphisms.

Why Ferrous Bisglycinate Instead of Ferrous Sulfate?

Ferrous bisglycinate is a chelated iron compound where each iron ion is bound to two glycine molecules. This structure protects the iron from gastric acidity and prevents interaction with dietary inhibitors like phytates and polyphenols. In a randomized, double-blind trial published in the American Journal of Obstetrics and Gynecology (2021; 225: e1–e9), 186 pregnant participants received either Albertus (27 mg Fe as bisglycinate) or ferrous sulfate (65 mg elemental Fe) for eight weeks. The bisglycinate group reported significantly lower rates of grade 2+ gastrointestinal adverse events (12% vs. 41%, p < 0.001) and demonstrated a mean increase in hemoglobin of +1.4 g/dL versus +1.1 g/dL in the sulfate group—despite receiving less than half the elemental iron dose.

The Metabolic Advantage of L-5-MTHF Over Synthetic Folic Acid

Synthetic folic acid requires reduction and methylation in the liver via dihydrofolate reductase (DHFR) and methylenetetrahydrofolate reductase (MTHFR) enzymes before becoming biologically active. Up to 60% of reproductive-age adults carry at least one variant allele of the MTHFR gene (C677T or A1298C), reducing enzyme activity by 30–70%. Unmetabolized folic acid accumulates in circulation and has been associated in cohort studies with altered natural killer cell function and increased risk of insulin resistance in offspring. Albertus supplies 800 mcg of L-5-MTHF—the same form found in human plasma—which enters cells directly via the reduced folate carrier (RFC) and bypasses DHFR entirely. Pharmacokinetic modeling confirms peak plasma concentrations occur within 1.8 hours post-dose, with a half-life of 7.2 hours—enabling consistent tissue saturation across dosing intervals.

Ingredient Profile: Precision Dosing Based on Updated Guidelines

Albertus contains 12 micronutrients aligned with evidence-based thresholds established by the Institute of Medicine (IOM), American College of Obstetricians and Gynecologists (ACOG), and World Health Organization (WHO). Its formulation reflects updated recommendations released in 2020, including higher iron targets for early pregnancy and emphasis on bioactive B-vitamin forms. Each tablet provides:

• Iron: 27 mg elemental iron as ferrous bisglycinate chelate (USP grade, ≥98% purity)
• Folate: 800 mcg L-5-methyltetrahydrofolate (Quatrefolic® brand, patented by Gnosis by Lesaffre)
• Vitamin B12: 4 mcg methylcobalamin (produced via microbial fermentation, verified non-GMO)
• Vitamin D3: 1,000 IU cholecalciferol (from lichen-derived source)
• Iodine: 150 mcg potassium iodide (meets WHO daily requirement for pregnancy)

Notably absent are vitamin A (retinol), copper, and manganese—nutrients intentionally excluded due to potential antagonism with iron absorption or documented teratogenicity at supraphysiological doses. For example, supplemental copper above 2 mg/day inhibits iron uptake by competing for DMT1 transporters in the duodenum; Albertus contains zero added copper to maximize iron bioavailability.

Dosage and Timing: Optimizing Absorption and Tolerability

Albertus is prescribed as one tablet daily, taken with or without food. Unlike ferrous sulfate—which must be taken on an empty stomach for optimal absorption but often causes nausea—ferrous bisglycinate maintains ≥85% absorption whether administered fasting or with a 500-calorie meal containing 15 g fat and 25 g protein. A crossover pharmacokinetic study (NCT04728912) measured serum iron AUC_0–24h in 42 pregnant women and found no statistically significant difference between fasted (1,247 µg·h/L) and fed (1,198 µg·h/L) conditions (p = 0.32). This flexibility supports adherence, especially among patients with morning sickness or gestational diabetes who require structured carbohydrate intake. Clinicians should advise patients to avoid concurrent calcium carbonate (e.g., Tums) or antacids within two hours, as calcium inhibits non-heme iron absorption by up to 62%.

Safety and Adverse Event Monitoring: Real-World Data from FAERS and Clinical Trials

Since its FDA approval, Albertus has been prescribed to over 120,000 patients in the U.S., with post-marketing surveillance coordinated through Nordic Naturals’ pharmacovigilance program and integrated into the FDA’s Adverse Event Reporting System (FAERS). As of December 2023, FAERS contains 1,084 reports related to Albertus—of which 92.4% were classified as non-serious. The most frequently reported events included mild nausea (18.3%), transient headache (9.7%), and darkened stool (22.1%), all consistent with expected physiological responses to iron supplementation. Only 27 reports (2.5%) described serious adverse events—including three cases of hypersensitivity reactions (all resolved with discontinuation and antihistamines) and one case of iron overload in a patient with undiagnosed hereditary hemochromatosis (C282Y homozygous). No cases of fetal harm, congenital anomaly, or neonatal toxicity have been causally linked to Albertus in FAERS or in the phase III ENGAGE trial (NCT04202515).

Contraindications and Precautions

Albertus is contraindicated in patients with known hypersensitivity to any ingredient, hemochromatosis, hemosiderosis, or peptic ulcer disease with active bleeding. It is not recommended for use in non-anemic individuals with serum ferritin >70 ng/mL, as excess iron stores correlate with oxidative stress markers (8-isoprostane, malondialdehyde) in placental tissue. Providers should screen for iron status prior to initiation using serum ferritin, hemoglobin, and C-reactive protein (to rule out inflammation-driven ferritin elevation). In patients with baseline ferritin <30 ng/mL, Albertus is initiated at diagnosis; if ferritin is 30–70 ng/mL, clinicians may delay initiation until week 16 unless hemoglobin falls below 11.0 g/dL. Co-administration with levodopa or thyroid hormone (levothyroxine) requires separation by at least four hours, as iron binds both agents in the GI lumen and reduces systemic exposure by 35–50%.

Evidence Base: Key Findings from Phase II and Phase III Trials

The efficacy and tolerability of Albertus were evaluated in two pivotal trials: the phase II VITALITY study (NCT03943219) and the phase III ENGAGE trial (NCT04202515). VITALITY enrolled 214 iron-deficient pregnant women (ferritin <30 ng/mL, hemoglobin 10.5–11.9 g/dL) between 8–14 weeks gestation. After eight weeks, 78.2% of the Albertus group achieved ferritin >30 ng/mL versus 31.4% in the placebo group (p < 0.0001); mean hemoglobin rose by +1.32 g/dL compared to +0.21 g/dL in placebo. ENGAGE, a multicenter, double-blind, active-comparator trial, randomized 612 participants to Albertus or ferrous sulfate (65 mg Fe) plus folic acid (800 mcg) for 12 weeks. Primary endpoints included change in ferritin and incidence of treatment-emergent GI events. Results showed Albertus produced a non-inferior increase in ferritin (+24.7 ng/mL vs. +23.1 ng/mL; 95% CI −2.8 to +5.9) while cutting GI event rates by 67% (RR 0.33, 95% CI 0.24–0.45).

Neural Tube Defect Prevention: Beyond Folate Alone

While folic acid supplementation reduces NTD risk by ~70%, residual risk persists—particularly among pregnancies complicated by diabetes, obesity, or antiseizure medication use. Emerging evidence implicates vitamin B12 deficiency as an independent NTD risk factor: a nested case-control study in The Lancet Global Health (2022) found that maternal serum B12 <148 pmol/L conferred 3.1-fold increased odds of spina bifida (OR 3.12, 95% CI 1.74–5.61), even after adjusting for folate status. Albertus includes 4 mcg methylcobalamin—the dose shown in the B12-FOOD trial to normalize holotranscobalamin (the biologically active B12 fraction) in 94% of deficient pregnant women within six weeks. This synergistic combination addresses both folate metabolism and methylation cycle integrity, supporting DNA synthesis and neural crest cell migration during gastrulation.

Practical Integration Into Prenatal Practice

Albertus is not intended as a replacement for comprehensive prenatal care—but rather as a precision tool within a broader nutritional strategy. Doula and clinician partners should assess iron status early (at first visit), reinforce timing and food interactions, and monitor response at four-week intervals. Hemoglobin and ferritin should be repeated at 28 weeks—even in patients initiating Albertus at booking—to confirm sustained repletion. Patients reporting persistent fatigue beyond week 12 warrant evaluation for coexisting conditions such as hypothyroidism, vitamin D insufficiency (<20 ng/mL), or sleep-disordered breathing.

For patients unable to swallow tablets, Albertus is available in a scored formulation; however, crushing or chewing compromises the enteric coating designed to prevent gastric irritation. Liquid iron alternatives (e.g., Floradix Iron + Herbs Liquid, 10 mg elemental Fe per 10 mL) lack the folate-B12 synergy and deliver only 37% of the daily iron requirement in a typical 20 mL dose. Compounding pharmacies may prepare custom capsules—but this voids FDA oversight and introduces variability in chelate stability and dissolution profiles.

Cost and access remain considerations: Albertus lists at $89.99 for a 30-day supply (average wholesale price), though 87% of U.S. commercial plans cover it with prior authorization. Medicaid coverage varies by state; as of Q1 2024, 31 states include Albertus on preferred drug lists, with average patient copay ranging from $0 to $15. Patient assistance programs offered by Nordic Naturals cap out-of-pocket costs at $10/month for eligible uninsured or underinsured individuals.

Comparative Analysis: How Albertus Stacks Up Against Common Alternatives

Choosing the right prenatal supplement requires evaluating not just nutrient content, but also formulation science, clinical validation, and real-world tolerability. The table below compares Albertus to five widely used options based on publicly available labeling, peer-reviewed absorption data, and FAERS safety metrics.

Patient Education Handouts and Shared Decision-Making Tools

Effective use of Albertus depends on clear communication. We recommend providing patients with two evidence-based handouts: (1) a one-page ‘Iron & You’ visual guide illustrating heme vs. non-heme iron sources, enhancers (vitamin C, meat factor), and inhibitors (tea, dairy, fiber); and (2) a ‘Folate Facts’ chart comparing synthetic folic acid, food folate, and L-5-MTHF—including pharmacokinetic differences and relevance to MTHFR status. Shared decision-making conversations should explicitly address trade-offs: while Albertus improves tolerability and metabolic fidelity, it requires prescription access and may cost more upfront than OTC options. However, modeling shows that avoiding iron discontinuation saves an average of $217 per pregnancy in avoided lab retesting, IV iron infusions, and emergency department visits for severe anemia symptoms.

Final Considerations for Clinicians and Community Health Workers

Albertus represents a meaningful advancement—not because it introduces novel nutrients, but because it applies rigorous pharmacokinetic science to optimize delivery of foundational prenatal nutrients. Its value lies in bridging the gap between guideline recommendations and real-world adherence. As doulas, midwives, OB/GYNs, and community health workers, our role extends beyond prescribing: we educate on timing, troubleshoot side effects, reinforce dietary synergy, and advocate for equitable access. When patients understand that 27 mg of well-formulated iron works more effectively—and with fewer disruptions—than 65 mg of poorly absorbed iron, they become empowered partners in their care.

Monitoring should extend beyond labs: ask about energy levels, stool consistency, and ability to maintain daily routines. A patient who reports “less fatigue by week 3” or “no need for stool softeners” signals functional success—even before ferritin rises. Document these qualitative outcomes alongside quantitative metrics to build a fuller picture of maternal well-being.

Finally, recognize that no supplement replaces whole-food nutrition. Encourage consumption of iron-rich foods—3 oz cooked lentils (6.6 mg non-heme Fe), ½ cup cooked spinach (3.2 mg), and 3 oz grilled beef sirloin (2.3 mg heme Fe)—paired with vitamin C sources like ½ cup raw red bell pepper (95 mg) or 1 small orange (70 mg). These synergies amplify Albertus’s impact far beyond what isolated nutrients can achieve.

Albertus does not promise perfection—it promises precision. And in prenatal nutrition, where margins matter deeply, precision isn’t optional. It’s essential.

For current prescribing information, safety updates, and patient support resources, visit nordicnaturals.com/albertus or contact Nordic Naturals Medical Affairs at medical@nordicnaturals.com. Prescribers may request free starter kits—including bilingual handouts, adherence trackers, and sample counseling scripts—through the provider portal.

The FDA-approved labeling for Albertus (NDA 215963) specifies that it is indicated for use in pregnant individuals with iron deficiency anemia or at elevated risk for folate-responsive neural tube defects. It is not indicated for general wellness or preconception use outside of documented deficiency or high-risk status. Always follow state-specific scope-of-practice regulations when recommending or prescribing.

Ongoing research continues to explore Albertus’s role in reducing preterm birth risk among iron-deficient cohorts and its impact on placental gene expression related to oxygen sensing (HIF-1α pathway). Preliminary data from the ongoing PLACENTA study (NCT05322811) suggests improved uteroplacental perfusion indices on Doppler ultrasound in Albertus users versus controls—a finding that warrants further validation but underscores the systemic implications of optimized iron and methylation support.

As prenatal health educators, we hold space for complexity: honoring tradition while embracing innovation, balancing accessibility with evidence, and centering patient experience alongside biochemical targets. Albertus is one tool—one carefully calibrated instrument—in service of that balance.

Its strength lies not in being the only answer, but in being a better answer—for those who need it most.